Skip to main content
ASND
NASDAQ Life Sciences

Ascendis Pharma的每周一次生长激素在特纳综合征试验中与每日疗法相匹配

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$231.12
Mkt Cap
$14.18B
52W Low
$124.06
52W High
$248.6
Market data snapshot near publication time

summarizeSummary

Ascendis Pharma宣布其TransCon hGH（lonapegsomatropin）在青春期前特纳综合征儿童中的2期New InsiGHTS试验在第52周的顶级结果为正面。每周一次的治疗显示出与每日生长激素somatropin相似的疗效和安全性，年化身高增长速度为9.05 cm/年，类似于每日治疗的9.04 cm/年。这是一个重要的积极发展，因为TransCon hGH已经获得FDA批准用于其他生长激素缺陷，这些结果支持其在特纳综合征（新适应症）中的潜在标签扩展。该公司计划在其3期HighLiGHts篮子试验中进行进一步研究，这将是这条产品线资产的关键催化剂。

在该公告发布时，ASND的交易价格为$231.12，交易所为NASDAQ，所属行业为Life Sciences，市值约为$141.8亿。 52周交易区间为$124.06至$248.60。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed ASND - Latest Insights

ASND
Apr 21, 2026, 5:16 PM EDT
Filing Type: 6-K
Importance Score:
8
Ascendis Pharma Calls $575M Convertible Notes for Redemption, Potential for Significant Share Dilution
Sentiment: Neutral
View Wiseek Article
ASND
Apr 20, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
7
Ascendis Pharma Completes Transition to Direct Nasdaq Listing for Ordinary Shares
Sentiment: Positive
View Wiseek Article
ASND
Apr 08, 2026, 4:02 PM EDT
Filing Type: 6-K
Importance Score:
7
Ascendis Pharma to Directly List Ordinary Shares on Nasdaq, Mandating ADS Exchange
Sentiment: Neutral
View Wiseek Article
ASND
Apr 08, 2026, 8:01 AM EDT
Source: GlobeNewswire
Importance Score:
9
Achondroplasia Combo Therapy Shows Unprecedented Non-Linear Growth Benefits in Ascendis Pharma Trial
Sentiment: Positive
View Wiseek Article
ASND
Apr 07, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
FDA Grants Orphan Drug Exclusivity for YUVIWEL, Now Commercially Available in US
Sentiment: Positive
View Wiseek Article
ASND
Apr 06, 2026, 4:13 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Yuviwel Gains 7-Year U.S. Orphan Drug Exclusivity for Ascendis Pharma
Sentiment: Positive
View Wiseek Article
ASND
Mar 17, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Ascendis Pharma Reports Positive Phase 2 Results for TransCon hGH in Turner Syndrome
Sentiment: Positive
View Wiseek Article
ASND
Mar 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Ascendis Pharma's Once-Weekly Growth Hormone Matches Daily Therapy in Turner Syndrome Trial
Sentiment: Positive
View Wiseek Article
ASND
Mar 16, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Ascendis Pharma Reports Strong Two-Year Data for Approved Achondroplasia Drug TransCon CNP
Sentiment: Positive
View Wiseek Article
ASND
Mar 16, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Pivotal Trial Shows TransCon CNP's Durable Two-Year Benefits in Achondroplasia
Sentiment: Positive
View Wiseek Article